Indications & Uses
Zepatid-12.5 is indicated for:
Pharmacology
Tirzepatide is an agonist of both the GIP receptor and the GLP-1 receptor. It is a modified peptide made of 39 amino acids, with a C20 fatty diacid moiety attached. This moiety lets it bind to albumin, and that prolongs its half-life. Tirzepatide binds selectively to both receptors and activates them, and these are the same receptors that native GIP and GLP-1 act on. It increases first and second-phase insulin secretion and lowers glucagon levels, and both effects depend on the glucose level.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Route of administration
Tirzepatide should be administered as a subcutaneous injection.
Dosing instructions
The recommended starting dosage is 2.5 mg injected subcutaneously once weekly. This 2.5 mg dosage is for starting treatment and is not meant for glycemic control. After 4 weeks, increase the dosage to 5 mg once weekly. If more glycemic control is needed, increase the dosage in 2.5 mg steps, but only after at least 4 weeks on the current dose. The maximum dosage is 15 mg injected subcutaneously once weekly. If a dose is missed, tell the patient to administer it as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. In each case, patients can then go back to their regular once weekly schedule. The day of weekly administration can be changed if necessary, as long as the time between the two doses is at least 3 days (72 hours).
Preparation and administration
The needle cover of the pre-filled syringe contains dry natural rubber (a derivative of latex), which may cause allergic reactions. Do not freeze, and do not use it if it has been frozen. Protect pre-filled syringes from light. Parenteral drug products should be inspected visually for particulate matter and discoloration before administration, and any pre-filled syringe showing particulate matter or discoloration should not be used. Handle it carefully. If the pre-filled syringe has dropped on a hard surface, do not use it. Do not dilute Tirzepatide, and do not administer it together with other drug solutions.
Administration instructions
Administer once weekly, any time of day, with or without meals. Inject it subcutaneously in the abdomen, thigh or upper arm, and rotate injection sites with each dose. When using it with insulin, administer them as separate injections and never mix them. It is acceptable to inject the two in the same body region, but the injections should not be adjacent to each other.
Side Effects
With tirzepatide, the side effects people report most often are nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia and abdominal pain.
Cautions & Contraindications
Warnings & Precautions
Patients using Tirzepatide should be told about the possible risk of MTC and what the symptoms of thyroid tumors look like. Once treatment has started, watch them closely for signs and symptoms of pancreatitis. If pancreatitis is suspected, stop Tirzepatide and begin suitable management. The risk of hypoglycemia can be lowered by reducing the dose of a sulfonylurea (or any other insulin secretagogue taken together with it) or of insulin. If a hypersensitivity reaction occurs, stop Tirzepatide, treat the patient promptly according to the standard of care, and keep monitoring until the signs and symptoms have resolved. In patients with renal impairment who report severe gastrointestinal adverse reactions, monitor renal function when starting Tirzepatide or increasing the dose. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy. If cholelithiasis is suspected, gallbladder diagnostic studies and appropriate clinical follow-up are indicated.
Contraindications
Don't give tirzepatide to anyone who is known to be allergic to tirzepatide or to any other component of the product. It is also contraindicated in people who have a personal or family history of medullary thyroid carcinoma (MTC), and in people with multiple endocrine neoplasia syndrome type 2 (MEN 2).
Pregnancy & Breastfeeding
Poorly controlled diabetes in pregnancy carries risks for both the mother and the baby. So Tirzepatide should be used during pregnancy only if the likely benefit is greater than the possible risk to the fetus.
For breastfeeding, the benefits of breastfeeding for the baby's development and health should be weighed together with the mother's clinical need for tirzepatide. The doctor should also consider any possible adverse effects on the breastfed infant, whether they come from tirzepatide or from the mother's underlying condition.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Use in Special Populations
Use in children and adolescents: Tirzep hasn't been shown to be safe or effective in patients under 18 years of age.
Overdose
If someone takes too much Tirzepatide, supportive treatment should be started according to the patient's signs and symptoms. The patient may need a period of observation and treatment for these symptoms, because the half-life of tirzepatide is approximately 5 days.
⚠️ In an emergency call 999 or go to the nearest hospital emergency department.
Storage
Keep Tirzepatide out of the reach and sight of children. Store it in a refrigerator at 2°C to 8°C. Don't freeze it, and protect it from light. If it has been frozen, don't use it. Tirzepatide should be taken and sold only on the prescription of a registered physician.
Drug Interactions
Common questions about Zepatid-12.5 12.5 mg
What is Zepatid-12.5 12.5 mg Injection?
Zepatid-12.5 12.5 mg Injection is a medicine that contains Tirzepatide. It is made by Popular Pharmaceuticals PLC. It belongs to the GLP-1 receptor agonists group of medicines.
What is Zepatid-12.5 used for?
Zepatid-12.5 is used for: Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus, Diabetes Mellitus.
What are the side effects of Zepatid-12.5?
With tirzepatide, the side effects people report most often are nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia and abdominal pain.
Can I take Zepatid-12.5 during pregnancy or while breastfeeding?
Poorly controlled diabetes in pregnancy carries risks for both the mother and the baby. So Tirzepatide should be used during pregnancy only if the likely benefit is greater than the possible risk to the fetus. Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
What happens if I take too much Zepatid-12.5?
If someone takes too much Tirzepatide, supportive treatment should be started according to the patient's signs and symptoms. The patient may need a period of observation and treatment for these symptoms, because the half-life of tirzepatide is approximately 5 days. In an emergency call 999 or go to the nearest hospital emergency department.
How should I store Zepatid-12.5?
Keep Tirzepatide out of the reach and sight of children. Store it in a refrigerator at 2°C to 8°C.
Can I take other medicines with Zepatid-12.5?
Some medicines can interact with Tirzepatide, for example: Insulin (Human) 30/70, Warfarin Sodium. Tell your doctor or pharmacist about every medicine you take.
Do I need a prescription for Zepatid-12.5?
Zepatid-12.5 is a prescription (Rx) medicine. Take it as your doctor advises.